Previous 10 | Next 10 |
Vascular Biogenics ( NASDAQ: VBLT ) was downgraded to Neutral from Buy at H.C. Wainwright after the company's ovarian cancer drug ofra-vec failed a phase 3 trial. Vascular stock fell post-market July 19 following the news. As of premarket July 20, VBLT shares have shed -...
VBL Therapeutics ( NASDAQ: VBLT ) on Tuesday said its phase 3 trial of its ovarian cancer treatment ofra-vec did not meet its main goals. The late-stage trial, called OVAL, did not meet the primary endpoints of achieving a statistically significant improvement in progr...
TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced top-line data from the Phase 3 OVAL clinical trial of ofra-vec (ofranergene oba...
TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced tha...
Vascular Biogenics Ltd. (VBLT) Q1 2022 Earnings Conference Call May 17, 2022, 08:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dror Harats - CEO Sam Backenroth - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Kevin DeGeeter - Oppenheimer RK Ramakant...
VBL Therapeutics press release (NASDAQ:VBLT): Q1 GAAP EPS of -$0.13 misses by $0.01. Revenue of $0.11M (-38.9% Y/Y) misses by $0.09M. At March 31, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $44.8M. VBL expects that its cash, cash equivalents...
OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (...
VBL Therapeutics (NASDAQ:VBLT) is scheduled to announce Q1 earnings results on Tuesday, May 17th, before market open. The consensus EPS Estimate is -$0.12 (flat Y/Y) and the consensus Revenue Estimate is $0.2M (+11.1% Y/Y). Over the last 1 year, VBLT has beaten EPS estimates 50% of the time a...
AER, ALLT, BPTH, OTCPK:ENGIY, OTCQB:GAXY, HD, HUYA, OTCQX:IMBBY, JD, JMIA, KMDA, MDWD, OBSV, ONON, PTN, REE, RSKD, SE, VBLT, VOD, WMT, XNET For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open
TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today ann...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...